Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

Next Previous
X
Search
Trial Profile

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Antineoplastics; Antineoplastics; Antineoplastics; Antineoplastics; Asparaginase; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Filgrastim; Hydroxycarbamide; Idarubicin; Mercaptopurine; Methotrexate; Methotrexate; Pegaspargase; Pegfilgrastim; Prednisolone; Prednisone; Rituximab; Vincristine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Golden Gate Study
  • Sponsors Amgen

    • Most Recent Events

    • 01 Aug 2024 Planned End Date changed from 2 Mar 2031 to 6 Oct 2031.
    • 01 Aug 2024 Planned primary completion date changed from 31 May 2026 to 5 Jan 2027.
    • 25 Jul 2024 Planned End Date changed from 28 Feb 2031 to 2 Mar 2031.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top